KRAS and cancer: Therefore, in patients with advanced cancer, we investigated whether mutation analysis of plasma-derived cfDNA has an acceptable level of concordance with routine clinical mutation analysis for common oncogenic mutations in BRAF, EGFR, KRAS, and PIK3CA. Tissue testing obtained from prior surgeries and biopsies was performed in the Clinical Laboratory Improvement Amendment (CLIA)–certified Molecular Diagnostic Laboratory at The University of Texas MD Anderson Cancer Center (MD Anderson).